Overview

A Phase I Clinical Trial to Evaluate the Effect of Renal Impairment on Pharmacokinetics of NOX-E36

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This is a multi center, open label, parallel group, single administration, phase I trial, in subjects with mild, moderate or severe renal impairment and a control group with normal renal function.
Phase:
Phase 1
Details
Lead Sponsor:
NOXXON Pharma AG